LeishGen: Advanced Genomic Platforms for Drug Resistance Biomarkers in Leishmania infantum
LeishGenApp and LeishGenR are Nano1Health’s cutting-edge solutions for detecting drug resistance biomarkers in Leishmania infantum, tailored to meet the needs of researchers, veterinarians, and physicians involved in managing leishmaniosis. These innovative platforms empower healthcare providers to select optimal treatments while helping slow the spread of drug resistance in One Health.
2 min read
LeishGenApp - Whole genome sequencing & 15 drug-resistance biomarker panel
LeishGenApp offers a deep dive into the Leishmania infantum genome, leveraging whole-genome sequencing and a specialized panel of 15 biomarkers as key indicators of drug resistance.
-
Genomic insights for precision care: in just two weeks, LeishGenApp delivers a comprehensive report on drug resistance, supporting researchers and clinicians in developing effective treatment plans.
-
Broad applicability: designed for both research and clinical settings, LeishGenApp is ideal for analyzing Leishmania infantum samples from humans and animals with cultured parasite isolates (10⁷ p/ml), aligning with the One Health approach.
LeishGenR - targeted detection of key drug-resistance biomarkers for clinical settings
LeishGenR simplifies the diagnostic process by detecting drug-resistance biomarkers to allopurinol, antimonials and miltefosine directly from clinical samples, eliminating the need for culturing.
-
Direct-from-sample accuracy: LeishGenR provides reliable detection of drug-resistance markers directly from clinical samples with lower parasite loads.
-
User-Focused for Clinicians: LeishGenR is designed with clinicians in mind, with a streamlined process and rapid feedback to support timely therapeutic decisions, enhancing patient outcomes and helping mitigate resistance spread in endemic regions.
